SETD2 and neoplasm: Antiangiogenic effects of agents such as Bevacizumab in combination with hypoxia-activated prodrugs or HIF-1 inhibitors and standard chemotherapies, however, have served as attractive strategies to target the hypoxic tumor microenvironment in triple negative breast cancer and gliomas [115, 134, 135].